8:00 AM–5:00 PM Wednesday, February 26

Pharmacologic Management of Pain: Expanding the Options, Improving Outcomes (001)

The pharmacologic management of acute and chronic pain is an important aspect of most if not all clinicians’ daily practices. However, strategies aimed at optimizing the use of nonopioid analgesics while mitigating the potential risks associated with opioid use can be difficult to implement. This course will provide timely, useful, and practical information about the use of opioid and nonopioid analgesics to treat adults with acute and chronic pain. The growing and evolving controversy of the therapeutic application of cannabis and cannabis-related products is an additional question facing providers.

With pain management-leading faculty for numerous well-regarded institutions, this course will help the learner better integrate various medications from different pharmacologic classes in order to optimize a rational polypharmacy approach to managing chronic pain, including comorbid symptoms of depression, anxiety, and sleep disturbances and implementing evidence-based assessment and treatment strategies supported by recent guidelines to optimize appropriate opioid analgesic use while applying a patient-centered approach to mitigate the risks of abuse, misuse, addiction, and diversion. Strategies to help improve opioid tapering and managing opioid use disorder will be explored.

Learning Objectives:

  • Apply the recent epidemiological evidence related to prescription opioid abuse and misuse, prescription opioid and heroin overdose deaths, and the risks associated with concomitant benzodiazepine use.
  • Review opioid analgesic medications to better understand the potential benefits and short-comings of abuse deterrent formulations.
  • Assess and interpret aberrant drug-related behaviors and integrate risk assessment tools/strategies into clinical practice.
Read more...
11:00 AM–12:00 PM Friday, February 28

Cutting Through the Hype: Marijuana and CBD Oil for Pain (203)

In 2018, the United States opioid epidemic raged on with more than 45,000 overdose deaths. Several states have legalized medical or recreational marijuana, and all forms of cannabis products are being used for the treatment of pain. In many cases, patients and prescribers prefer using cannabis as an alternative to opioids, but the strength of the evidence for this is not widely understood. This session will provide learners with knowledge of the strength of evidence for using cannabis products for treatment of pain and opioid reduction as well as help learners gain an understanding of the acute and chronic risks of THC/CBD treatments.

Cannabinoid Biology

David Edwards

CBD Oil for Pain?

Thomas Pittelkow

Cannabis to Reduce Opioid Use?

Mark Wallace

Learning Objectives:

  • Describe the biology of the endocannabinoid system and how exogenous cannabinoids are hypothesized to treat pain.
  • Assess the strength of peer-reviewed evidence for the use of cannabis and CBD oil for the treatment of pain.
  • Explain the risks and benefits of cannabis use for pain treatment.
Read more...
Moderator:

Mark Wallace

Co-Presenters:

David Edwards

Thomas Pittelkow

3:00 PM–4:00 PM Saturday, February 29

Headache Rapid-Fire: Headache Management Pearls for the Pain Provider (315)

Headache, facial pain, and interventions commonly are are referred to a pain specialist, as they often are under-represented in pain training. This will be a fast-paced, case-based, audience-involved session focusing on practical clinical pearls in the diagnosis and treatment of headache disorders seen in pain medicine practices.

Headache Rapid-Fire Panel

James Watson, Alexander Feoktistov, Meredith Barad

Learning Objectives:

  • Recognize common headache syndromes seen in pain medicine practices and evidence-based treatment recommendations.
  • Interpret the role of interventional procedures in various headache syndromes.
  • Identify unique treatments appropriate for spontaneous intracranial hypotension headache, cluster headache, severe acute on chronic headache, and refractory chronic daily headaches.
Read more...
11:15 AM–12:15 PM Saturday, February 29

Opioid Therapy 2020: Past, Present, and Future (306)

This session will discuss the challenges surrounding the safe and effective use of opioids in chronic noncancer and cancer pain populations. An update on current evidence on opioid efficacy for chronic noncancer pain will be provided. Opioid treatment guidelines will be reviewed. Additional methods to mitigate risk will be described.

Opioid Safety: Defining and Mitigating Risks

ToNhu Vu

Understanding Guidelines and Recommendations: Cancer and Non-Cancer Pain

Jianren Mao

The Role of Opioids in Chronic Pain Management: Assessing the Evidence

David Provenzano

Learning Objectives:

  • Define opioid guidelines for cancer and chronic pain.
  • Employ methods to mitigate risk when using opioids.
  • Characterize current evidence for opioid efficacy in noncancer chronic pain.
Read more...
Moderator:

David Provenzano

Co-Presenters:

ToNhu Vu

Jianren Mao

Going Deeper into Opioid Deprescribing: Addressing the Concerns of Prescribers and Patients to Optimize Outcomes (302)

Published in Saturday, February 29

This session clarifies the assessment of opioid use behaviors and delivery of individualized, patient-centered opioid reduction strategies across the continuum of opioid use and patient behaviors. The multidisciplinary faculty will summarize the best available evidence and emphasize practical tools rooted in patient safety for optimized patient engagement and success.

Demystifying Opioid Deprescribing Across the Continuum While Providing Individualized, Whole Person Pain Care

Aram Mardian

Addressing Complexities of Opioid Deprescribing with Patient-Centered Approaches: Supportive Psychological Strategies, Low-Cost Technologies, and Self-Management Tools

Beth Darnall

Seamless Integration of Opioid Use Disorder Management in Patients with Chronic Pain

Anita Karnik

Learning Objectives:

  • Use three behavioral strategies to enhance readiness to engage in a collaborative opioid taper.
  • Distinguish opioid use disorder from complex persistent opioid dependence and simple opioid dependence.
  • Describe recent federal cautions related to opioid deprescribing.
Read more...
Subscribe to this RSS feed